Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory dermatosis of the body folds, characterized by nodules, abscesses, sinus tracts and numerous comorbidities, significantly impairing patients' quality of life (QoL). 1-5 Among skin diseases, HS has the largest impact on QoL. 6 Few specific instruments are available to assess, in a comprehensive, psychosocial perspective, the burden of HS, 7 and no qualitative studies exploring the experience of HS patients and their relationship with the physician are currently available.
A mixed methodology has been applied: patient-only and a physician-only focus groups 9 were created to capture the experience and perspective of the disease on both sides; a modified Delphi method 10 was then applied to assess the level of convergence of both opinions about the items selected and their weight within the disease experience of HS.
A clinical psychologist, acting as facilitator, conducted two distinct roundtable meetings: one included nine patients (6 women; aged 19-55 years) affected by HS for ≥24 months, while the other roundtable meeting included ten dermatologists (6 women) with well-documented experience in the research field of the impact of chronic skin diseases on QoL. Both patients and physicians were deeply interested in the development of a new tool, had knowledge of HS and were motivated to share their knowledge and experience.
The first endpoint was to identify the most significant aspects of the patients' experiences, with the purpose of selecting the questionnaire items. During the meetings, questions were asked by a facilitator regarding patients' emotions, interpretations and expectations related to HS and the impact of the disease on daily life and social relationships. Items were divided into 10 dimensions; each dimension encompassed 2-6 items for a total of 35 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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items. Patients and physicians were asked to express their degree of consent on each statement using a 5-point Likert scale (1 = highest disagreement to 5 = complete agreement). A consensus was reached with an agreement of >66%. Items with a lower percentage of agreement were considered as 'not-solved' in terms of consensus and eliminated (percentage of agreement shown in Table 1 ). According to the results obtained by the Delphi procedure, the 10 identified dimensions were revised and only the items with a positive consensus from both patients and physicians were selected. A final meeting with 10 dermatologists chaired by a clinical psychologist acting as facilitator was held to discuss the results obtained. A rewording of the items was performed to further simplify and design an easy questionnaire ( Fig. 1) .
HIDRAdisk is designed to be completed by the patient with the dermatologist, fostering their communication. Being a visual instrument, with the answers shown graphically through a polygon, HIDRAdisk gives an immediate picture of the burden of the disease, allowing patients and physicians to visualize the course of the disease over time. When the burden of disease decreases, the area of the polygon shrinks, providing an immediate and intuitive representation of the progress achieved.
HIDRAdisk could help improve the management of the disease and increase patients' feeling of control over their disease.
HIDRAdisk is currently under psychometric validation in 140 patients with different degrees of HS severity, correlating the HIDRAdisk outcomes with the Dermatology Life Quality Index and the Skindex-16. The tool will be developed on electronic devices, offering dermatologist a quick and easy response during routine clinical practice or clinical studies.
AbbVie participated in the conduct and financial support of the project, as well as in interpretation of the results, review and approval of the manuscript. 
Doctor-patient relationship
HS is not only a severe but also a chronic disease and an ideal patientphysician relationship should allow the patient to be told as early as possible the diagnosis and to understand the main features of HS 100 100
HS is not only a severe but also a chronic disease and an ideal patientphysician relationship should allow the patient to receive adequate information on the available options for therapy 100 100
HS is not only a severe but also a chronic disease and an ideal patientphysician relationship should allow the patient to be met and understood not only as a patient but also as a person 100 90
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